INTRODUCTION: This study was an examination of the refractive results and complications encountered with implantation of the Eyecryl phakic intraocular lens (IOL) (Biotech Vision Care, Luzern, Switzerland).
METHODS: IOL recipients with a follow-up period of at least 2 years were included the study. Uncorrected and corrected distance visual acuity (UDVA and CDVA, respectively), central endothelial cell density (ECD), and procedure-related complication data were recorded.
RESULTS: The study included 52 eyes from 26 patients. The efficacy index (postoperative UDVA/preoperative CDVA) was 1.32±1.09 in the first year and 1.39±1.03 in the second year. The safety index (postoperative CDVA/preoperative CDVA) was 1.69±1.16 at the last follow-up. None of the patients lost 2 or more lines of CDVA. The mean ECD loss was 4.51±9.69% at 1 year (p=0.005). There was no statistically significant ECD loss between the 1- and 2-year follow-up visits (p=0.794).
DISCUSSION AND CONCLUSION: The results of Eyecryl phakic IOL implantation were favorable in terms of efficacy and safety.